Previous Article | Next Article 
Journal of Virology, March 1999, p. 2126-2135, Vol. 73, No. 3
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Human Immunodeficiency Virus Type 1 Integrase Protein Promotes
Reverse Transcription through Specific Interactions with the
Nucleoprotein Reverse Transcription Complex
Xiaoyun
Wu,1
Hongmei
Liu,1
Hongling
Xiao,1
Joan A.
Conway,1
Eric
Hehl,2
Ganjam V.
Kalpana,3
Vinayaka
Prasad,2 and
John C.
Kappes1,4,5,*
Departments of
Medicine1 and
Microbiology,4 University of Alabama at
Birmingham, Birmingham, Alabama 35294;
Birmingham Veterans
Affairs Medical Center Research Service, Birmingham, Alabama
352335; and
Departments of Molecular
Genetics3 and
Microbiology and
Immunology,2 Albert Einstein College of
Medicine, Bronx, New York 10461
Received 21 August 1998/Accepted 20 November 1998
 |
ABSTRACT |
The human immunodeficiency virus type 1 (HIV-1) integrase protein
(IN) is essential for integration of the viral DNA into host cell
chromosomes. Since IN is expressed and assembled into virions as part
of the 160-kDa Gag-Pol precursor polyprotein and catalyzes integration
of the provirus in infected cells as a mature 32-kDa protein, mutations
in IN are pleiotropic and may affect virus replication at different
stages of the virus life cycle in addition to integration. Several
different phenotypes have been observed for IN mutant viruses,
including defects in virion morphology, protein composition, reverse
transcription, nuclear import, and integration. Because the effects of
mutations in the IN domain of Gag-Pol can not always be distinguished
from those of mutations in the mature IN protein, there remains a
significant gap in our understanding of IN function in vivo. To
directly analyze the function of the mature IN protein itself, in the
context of a replicating virus but independently from that of Gag-Pol,
we used an approach developed in our laboratory for incorporating proteins into HIV virions by their expression in trans as
fusion partners of either Vpr or Vpx. By providing IN in
trans as a Vpr-IN fusion protein, our analysis revealed,
for the first time, that the mature IN protein is essential for the
efficient initiation of reverse transcription in infected cells and
that this function does not require the IN protein to be enzymatically
(integration) active. Our findings of a direct physical interaction
between IN and reverse transcriptase and the failure of heterologous
HIV-2 IN protein to efficiently support reverse transcription indicate that this novel function occurs through specific interactions with
other viral components of the reverse transcription initiation complex.
Studies involving complementation between integration- and DNA
synthesis-defective IN mutants further support this conclusion and
reveal that the highly conserved HHCC motif of IN is important for both
activities. These findings provide important new insights into IN
function and reverse transcription in the context of the nucleoprotein
reverse transcription complex within the infected cell. Moreover, they
validate a novel approach that obviates the need to mutate Gag-Pol in
order to study the role of its individual mature components at the
virus replication level.
 |
INTRODUCTION |
The retroviral integrase (IN)
protein catalyzes integration of the provirus and is essential for
persistence of the infected state in vivo. Significant progress has
been made in our understanding of this critical enzyme, especially its
protein structure and the biochemical mechanism of the catalytic
integration reaction (5, 14, 30). Human immunodeficiency
virus type 1 (HIV-1) IN is expressed and assembled into the virus
particle as a part of a larger, 160-kDa Gag-Pol precursor polyprotein
(Pr160Gag-Pol) that contains other Gag (matrix, capsid,
nucleocapsid, and p6) and Pol (protease, reverse transcriptase [RT],
and IN) components. After assembly, Pr160Gag-Pol is
proteolytically processed by the viral protease to liberate the
individual Gag and Pol components, including the 32-kDa IN protein (for
a review, see reference 48). Recent studies on IN
function using replicating virus (in vivo) have suggested that in
addition to catalyzing integration of the viral cDNA, IN may have other
effects on virus replication (23, 35, 41). In studies with
proviral clones, it is obvious that IN gene mutations can affect virus
replication at multiple levels. Mutations in the IN gene can affect the
Gag-Pol precursor protein and alter assembly, maturation, and other
subsequent viral events. IN gene mutations can also affect the mature
IN protein and its organization within the virus particle and the
nucleoprotein preintegration complex. Therefore, such mutations are
pleiotropic and may alter virus replication through various mechanisms
and at different stages in the virus life cycle. At least in part, this
likely explains the diverse phenotypes that have been reported for IN mutant viruses. These have included viruses with defects in assembly, virion morphology, reverse transcription, nuclear import, and integration of the provirus (3, 7, 16, 44, 46). While it is
obvious that a full understanding of IN function requires analysis in
higher-ordered systems that accurately reproduce both the viral and
host cell environments, the pleiotropic nature of IN mutations has
complicated such studies, and thus there remains a significant gap in
our understanding of IN function in vivo.
Numerous in vitro studies have examined the biochemical and genetic
properties of retroviral IN proteins and have provided most of the
information for the currently accepted mechanism of the integration
reaction. Using purified IN and oligonucleotides that represent the
viral DNA ends, the in vitro integration reaction proceeds in two
steps: IN removes two nucleotides from the 3' terminus of the viral DNA
(terminal cleavage), which is then joined to a break in the cellular
DNA (strand transfer) (6, 22, 43). Through amino acid
sequence alignment and in vitro activity studies of wild-type and
mutant IN proteins, distinct functional domains that are conserved
among retroviruses have been identified (12, 15, 33, 53). In
the case of HIV-1, the N-terminal domain (residues 1 to 50) contains a
highly conserved HHCC motif. Mutation of this motif has variable
effects on 3' processing and strand transfer, and its function remains
poorly understood (15, 36, 51, 52). The central region
(residues 51 to 212) contains the invariant acidic residues D64, D116,
and E152. Mutation of any of these residues causes a loss of all IN
activity in vitro, suggesting that this region is the catalytic center
of the enzyme (15, 36, 51). The carboxyl-terminal region
(residues 213 to 288) is least conserved and possesses nonspecific DNA
binding properties. Certain mutations within the C-terminal region may not significantly affect the activity of IN in vitro, while causing a
dramatic loss of virus infectivity (10, 16, 56).
Reverse transcription is catalyzed by RT, and although reverse
transcription can occur in vitro with recombinant RT, template, and
primer, the process is more complex in vivo. In the context of a
replicating virus, complete synthesis of the viral cDNA is not as
simple as putting together different proteins and nucleic acids;
rather, it is a complex, multistep process involving a number of
transitional structures. Within the infected cell, reverse transcription takes place in the context of a nucleic acid-protein (nucleoprotein) complex that includes other viral and cellular factors
(7, 18, 19, 29, 42). Moreover, synthesis of the viral cDNA
is greatly dependent on the proper execution of numerous molecular
events that precede reverse transcription. In the case of HIV-1,
several viral regulatory proteins are known to affect reverse
transcription. Nef mutant viruses exhibit a 5- to 50-fold reduction in
DNA synthesis (2, 45). Pseudotyping with vesicular
stomatitis virus glycoprotein (VSV-G) complements this defect,
indicating that Nef affects uncoating and, in turn, reverse
transcription (1). Vif mutant viruses produced by primary cells (nonpermissive) are defective in viral DNA synthesis (47, 54). It remains unknown whether this is due to a direct or
indirect effect of Vif on reverse transcription (9, 38).
Recently, Tat was shown to be required for efficient reverse
transcription in infected cells (25). The nucleocapsid
protein, which facilitates strand transfer, may also increase the
efficiency of reverse transcription (24, 37). Mutations of
the critical proline residues within the capsid domain of
p55Gag, which are important for binding cyclophilin A,
result in virions that enter cells normally but fail to initiate viral
DNA synthesis (4, 21, 40, 49). Taken together, these results
have shown that reverse transcription can be affected by multiple
factors and at various levels of the virus life cycle. In the absence of a detailed understanding of the molecular mechanisms involved in the
formation of infectious virus and the structure and composition of the
reverse transcription complex, it is difficult to differentiate between
factors that are specific and directly affect reverse transcription and
those that involve other steps in virus replication, such as assembly,
maturation, and uncoating.
Most in vivo studies of IN function have utilized virus derived from IN
mutant proviral DNA, where detection of an integrated provirus was the
primary marker for IN activity. Since mutations in the HIV-1 IN gene
can cause defects in virus replication prior to integration, assays
that rely on integration are not always useful for dissecting the
function of IN at the virus replication level. By monitoring for
products of reverse transcription in infected cells, certain HIV-1 IN
mutants have been found to be defective in steps at or prior to the
viral DNA synthesis stage. IN deletion mutant virus or those with
mutations in the HHCC motif of IN have been shown to produce 10- to
20-fold less viral DNA following infection (16, 17, 35, 41).
Although these viruses are normal in proteolytic processing, virion
protein composition, encapsidation of the genomic RNA, and
virion-associated RT activity, it has remained unknown at what level(s)
such IN mutations affect the virus life cycle (35, 41). The
production of infectious retroviral particles occurs through a highly
coordinated sequence of events, and numerous examples have illustrated
that even subtle changes in this process can have dramatic affects on
events early in the virus life cycle, such as reverse transcription.
The sensitivity of viral DNA synthesis to events that occur earlier is
reflected by the high proportion of virions that are unable to initiate reverse transcription. Thus, it is apparent that an impairment in viral
DNA synthesis may be a consequence of other defects and may not
necessarily represent an intrinsic defect in reverse transcription itself.
To directly analyze the function of the mature IN protein itself, we
used an approach developed in our laboratory that utilizes HIV
accessory proteins (Vpr and Vpx) as vehicles to incorporate other
proteins into HIV virions by their expression in trans as fusion proteins (39, 57-59). By expression as fusion
partners of Vpr, we recently demonstrated that fully functional RT and IN could be efficiently incorporated into HIV-1 particles independently of the Gag-Pol precursor protein (39, 57). Moreover, we have demonstrated that virions derived from an RT- and IN-minus proviral clone were infectious and replicated through a complete cycle of
infection when complemented in trans with Vpr-RT and IN
fusion proteins. These findings have enabled us to unlink the function of the mature IN protein from that of the Gag-Pol precursor protein and
suggested that it was possible to directly analyze IN protein function
by introducing mutations into IN without interfering with Gag-Pol
function and other late-stage events that could affect reverse
transcription. More recent studies from our laboratory and others have
shown that the defect in the replication of various IN mutant viruses
could be complemented by the Vpr-IN fusion protein (20, 39).
However, these studies did not address the specific nature of the
defect or the mechanism by which the trans-IN protein was
able to complement the impaired phenotype. In this study, we expressed
and incorporated functional IN protein into virions in trans
to analyze at what stage in the virus life cycle different IN mutations
affect HIV-1 reverse transcription. Our analysis has revealed, for the
first time, that the mature IN protein itself is required for viral DNA
synthesis in vivo. Our analysis also demonstrated that this function of
the IN protein is mediated through specific interactions with other
components of the nucleoprotein reverse transcription complex after
virus entry and uncoating but prior to or at the initiation stage of
viral DNA synthesis. These findings provide important new insights into
IN function and the reverse transcription process as it occurs in vivo.
 |
MATERIALS AND METHODS |
Cells, HIV-1 clones, and expression plasmids.
The 293T,
HeLa-CD4, and HeLa CD4-LTR/
-gal indicator cell lines (32)
were maintained in Dulbecco's modified Eagle's medium supplemented
with 10% fetal bovine serum, 100 U of penicillin and 0.1 mg of
streptomycin per ml. The wild-type pSG3wt, RT-IN-minus
pSG3S-RT, IN-minus pSG3S-IN, and IN mutant
pSG3D116A proviral clones have been described previously
(38, 57). The RNase H mutant pSG3D443N proviral
clone was constructed by replacing the aspartic acid residue with an
asparagine residue at position 443 of RT, using PCR methods. This
mutation inactivated the RNase H activity of RT. The pHy-SG3
INAA35A clone was constructed by inserting alanine residues
into the hygromycin-resistant pHy-SG3 clone at each of the three amino acid positions that comprise the catalytic center of the IN protein (D64A, D116A, and E152A). The Vpr-IN, Vpr-RT, and Vpr-RT-IN expression vectors were described earlier (38, 57).
Vpr-INH12A, Vpr-INH16A,
Vpr-IN
22, and Vpr-
PCIN were constructed
by PCR-based mutagenesis of pLR2P-vprIN. The Vpr-
PCIN
plasmid was constructed to disrupt normal proteolytic cleavage and
liberation of IN protein. The leucine residue at position P1' of the
RT-IN cleavage site was replaced with an isoleucine residue. The
Vpr-INF185A expression vector was constructed by inserting
the F185A mutant IN (provided by Alan Engelman) into pLR2P-vprIN. The
Vpr-HIV-2 IN expression plasmid (pLR2P-vprIN2) was
constructed by inserting a BglII/XhoI
IN-containing DNA fragment of HIV-2ST into pLR2P-vprIN. The
PCR-amplified IN fragment included 30 bp of RT sequence, which was
included to preserve the natural protease cleavage site at the N
terminus of IN.
Transfections and virus purification.
DNA transfections were
performed with monolayer cultures of 293T cells by the calcium
phosphate DNA precipitation method according to the recommendations of
the manufacturer (Stratagene). Unless otherwise noted, all
transfections were performed with 4 µg of each plasmid. Supernatants
from the transfected cultures were collected after 48 h, clarified
by low-speed centrifugation (1,000 × g, 10 min), and
analyzed for RT activity as described previously (13) and
for HIV-1 capsid protein concentration by p24 antigen enzyme-linked
immunosorbent assay (ELISA) (Coulter Inc.). Virions were pelleted by
ultracentrifugation through cushions of 20% sucrose with a Beckman
SW41 rotor (125,000 × g, 2 h).
Semiquantitative detection of viral DNA.
The PCR technique
used to monitor the synthesis of viral DNA in infected cells was
similar to those described earlier (4, 41, 54). Briefly,
500-ng equivalents (p24 antigen) of transfection-derived virus were
used to infect one million HeLa-CD4 cells. To control for variation in
virus entry by the different mutant viruses, the intracellular p24
antigen concentration of each virus was determined 4 h after
infection as described earlier (39). At 4 and 18 h
after infection, cells were lysed and total DNA was extracted by
organic methods. The DNA extracts were resuspended in 200 µl of
distilled water and treated with the DpnI restriction endonuclease to digest bacterially derived plasmid DNA (from
transfection). The viral cDNA synthesized de novo following infection
is resistant to cleavage by DpnI. To eliminate any effect of
differential virus entry on the detection of viral DNA products in
infected cells, the DNA extracts were normalized to 250 pg of p24
antigen for PCR amplification. The wild-type DNA extract was adjusted
to 250 pg (100%), 100 pg (40%), 40 pg (16%), 16 pg (6.4%), and 6.4 pg (2.5%). The DNA extracts were then subjected to 30 rounds of PCR amplification with primers designed to detect early (R-U5 [sense nucleotides 1 to 22, 5'-GGTCTCTCTGGTTAGACCAGA-3'; antisense
nucleotides 181 to 157, 5'-CTGCTAGAGATTTTCCACACTGAC-3']),
intermediate (U3-U5 [sense nucleotides 8687 to 8709, 5'-ACACACAAGGCTACTTCCGTGA-3'; antisense nucleotides 181 to
157, 5'-CTGCTAGAGATTTTCCACACTGAC-3']), and late (R-gag
[sense nucleotides 1 to 22, 5'-GGTCTCTCTGGTTAGACCAGA-3'; antisense nucleotides 355 to 334, 5'-ATACTGACGCTCTCGCACCCAT-3']) products of reverse
transcription. The PCR products were separated on a 1.5% agarose gel
and visualized by ethidium bromide staining.
Analysis of RT-IN interaction.
Expression of the recombinant
glutathione S-transferase (GST) and GST-IN proteins was
induced with 1 mM IPTG
(isopropyl-
-D-thiogalactopyranoside), and the bacterial
pellet was lysed in buffer Y-0.2 M NaCl (50 mM HEPES [pH 7.0], 1 mM
EDTA, 0.5% IGEPAL CA-630, 200 mM NaCl, 2 µg of aprotinin per ml, 2 µg of leupeptin per ml, 2 µg of pepstatin A per ml, 18 µg of
phenylmethylsulfonyl fluoride per ml) via six freeze-thaw cycles,
followed by lysozyme (0.2 g/liter) treatment for 30 min. The lysates,
recovered via centrifugation at 101,000 × g for 30 min, were bound to a 0.5-ml suspension of freshly prepared glutathione
beads (G-beads). The beads bound to GST and GST-IN were washed three
times with 50 ml of buffer Y-0.2 M NaCl, followed by quantitation of
the protein along with standards by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The expression
of recombinant HIV-1 RT heterodimers was induced and lysis was
performed as described previously (31), except that the
lysis buffer contained 300 mM NaCl and HEPES (pH 7.2). After
extraction, the samples were centrifuged at 101,000 × g for 30 min, and the lysates were recovered as
supernatants. Fifty microliters of beads bound with equimolar
quantities of GST or GST-IN proteins was incubated with 100 µl of
crude bacterial lysates containing RT heterodimer in HND buffer (20 mM
HEPES [pH 7.0], 120 mM NaCl, 4 mM MgCl2, 5 mM
dithiothreitol, 0.1% IGEPAL, 100 mg of bovine serum albumin per ml, 2 µg of aprotinin per ml, 2 µg of leupeptin per ml, 2 µg of
pepstatin A per ml, 18 µg of phenylmethylsulfonyl fluoride per ml).
The reaction was allowed to proceed with slow mixing for 1 h at
4°C. The beads were washed five times with 1 ml of buffer Y-50 mM
NaCl. The washed pellets were resuspended in SDS-PAGE loading buffer,
boiled for 10 min, cleared by centrifugation, and applied to
SDS-polyacrylamide gels.
 |
RESULTS |
Certain IN mutant viruses are impaired in reverse
transcription.
To study the function of the mature IN protein, we
first generated and characterized different IN mutant viruses for their ability to synthesize viral DNA. These included S-IN (IN minus), H12A
and H16A (the mutations disturb the conserved HHCC motif located in the
N terminus), F185A (the mutation is structurally positioned near the
catalytic center),
22 (the mutation deletes 22 amino acids from the
C terminus), and D116A (the mutation destroys enzymatic activity).
HeLa-CD4 cells were infected with 500 ng of each virus and analyzed
18 h later for the presence of early (R-U5), intermediate (U3-U5),
and late (R-gag) DNA products of reverse transcription. Ten- to 20-fold
less early (R-U5) DNA was detected in cells infected with all of the IN
mutant viruses, with the exception of D116A (Fig.
1, lanes 2 to 7). Similar changes were
detected for the intermediate and late DNA products. No viral DNA was
detected in cells that were infected with the control S-RT virus
(lacking both RT and IN [57]). The RNase H-defective RT mutant virus (D443N) produced the early R-U5 DNA product in amounts
similar to those produced by wild-type virus, but the levels of the
intermediate and late DNA products were dramatically reduced,
indicating that the strong-stop DNA product is relatively stable for at
least 18 h in infected cells. At 4 h after infection, the
relative proportions of wild-type and IN mutant DNA products were
similar to those measured at 18 h (data not shown). The reverse transcription products (detected by PCR) were confirmed to have been
synthesized within the infected cells, since zidovudine completely inhibited the detection of mutant and wild-type viral DNAs (data not
shown). Similar concentrations of intracellular CA protein were
detected for both the wild-type and mutant viruses, indicating that the
impaired DNA synthesis of the IN mutants was not due to a block at the
level of virus entry (Table 1). Also, all
of the other mutant viruses (except the S-IN mutant) exhibited normal levels of virion-associated RT activity (Table 1). The analysis for
two-long-terminal-repeat circular viral DNA (data not shown) confirmed
that the nuclear import of nascent viral cDNA of each IN mutant was not
impaired in HeLa cells (dividing cells).

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 1.
Mutations in IN can impair reverse transcription.
Wild-type (pSG3wt) and mutant (S-IN, H12A, H16A, F185A,
22, D116A, S-RT, and D443N) proviral clones were introduced into
293T cells by calcium phosphate DNA transfection methods. Forty-eight
hours later, culture supernatants were filtered through
0.45-µm-pore-size filters and analyzed by HIV-1 p24 antigen ELISA
(Coulter Inc.). The virus-containing culture supernatants were
normalized to 500 ng of p24 antigen (CA), treated with RNase-free DNase
H (20 U/ml for 2 h) (Promega Corp.), and placed on cultures of
HeLa-CD4 cells at 37°C. After 4 h, the cell monolayers were
washed, trypsinized, resuspended in fetal bovine serum, and divided
into two aliquots. One aliquot set (which contained 1/10 of the total
number of cells) was lysed in phosphate-buffered saline containing 1%
Triton X-100 and analyzed by p24 antigen ELISA to quantify
intracellular CA protein (Table 1). The other aliquot set was placed
back in culture medium at 37°C for an additional 14 h. The cells
were then washed, and total DNA was extracted by organic methods. For
each DNA extract, 250-pg equivalents (p24 antigen) were analyzed by PCR
methods for early (R-U5), intermediate (U3-U5), and late (R-gag) viral
DNA products of reverse transcription. The amplified products were
resolved on 1.5% agarose gels and stained with ethidium bromide. To
assess the relative amount of each of the amplified DNA products, four
serial 2.5-fold dilutions of the wild-type (SG3wt) DNA were
analyzed in parallel. The undiluted 250-pg sample was arbitrarily set
to 100. As standards, 10 to 6,250 copies of the pSG3wt
clone were also analyzed by PCR under identical conditions. As a
control for the efficiency of DpnI cleavage of potential
carryover plasmid DNA, 6,250 copies of pSG3wt DNA were
analyzed after digestion with DpnI as described previously
(26). The virus origin of the ethidium bromide-stained DNA
products was confirmed by Southern blot analysis with a homologous
nick-translated probe (data not shown). The ethidium bromide staining
intensity of each amplified DNA produce was measured with a Lynx 5000 molecular biology workstation (Applied Imaging, Santa Clara, Calif.).
The data shown are from a representative experiment that was repeated
three times, each time with independent transfection-derived virus
preparations.
|
|
Since circular forms of viral DNA in the nuclei of infected cells can
express Tat protein, we exploited the HeLa-CD4-LTR/
-gal cell line
(32) as a biological indicator for a defect in viral DNA
synthesis. Table 1 shows that the infectivity of the IN mutant viruses
was decreased 20- to 100-fold compared to that of the integration-defective D116A virus (which supports wild-type levels of
viral DNA synthesis). These results indicated that the loss of
infectivity could not be explained solely by a defect in integration, but rather, they suggested a defect at the level of viral DNA synthesis. These results are consistent with our analysis for viral
DNA. Taken together, these results show that mutations in certain
regions of IN can impair DNA synthesis in infected cells.
trans-IN protein restores viral DNA synthesis to IN
mutant viruses.
Mutations in the IN gene may affect virus
replication at multiple levels. To examine whether changes in the
Gag-Pol precursor protein or the IN protein were responsible for the
defect in reverse transcription, the Vpr-IN fusion protein was
expression in trans with each of the different IN mutant
viruses. Figure 2A confirms that the
Vpr-IN fusion protein was efficiently packaged and processed by the
viral protease to liberate the mature 32-kDa IN protein. Mutant viruses
that contained the Vpr-IN fusion protein (trans-IN) exhibited a 5- to 10-fold increase in the synthesis of early, intermediate, and late viral DNA products (Fig. 2B). These results demonstrate that the Vpr-IN fusion protein, which was assembled into
virions together with mutant Gag-Pol precursor protein (S-IN, H12A,
H16A, F185A, or
22, respectively), restored viral DNA synthesis. Using the MAGI assay, we confirmed that Vpr-IN also restored virus infectivity, to between 15 and 58% of that of wild-type virus (Table
1). It is important to note that while the trans-IN protein complemented viral DNA synthesis and infectivity, it did not correct the defect in Gag processing (excess p39) or virion-associated RT
activity (Fig. 2A and Table 1).

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 2.
Analysis of Vpr-IN-complemented virions. Four micrograms
of the wild-type and mutant proviral DNA clones was individually
transfected ( ) into 293T cells and cotransfected (+) with the
pLR2P-vprIN expression plasmid. Forty-eight hours later, the culture
supernatants were collected, passed through 0.45-µm-pore-size
filters, and analyzed for HIV-1 p24 antigen concentration by ELISA. (A)
Immunoblot analysis. One-half of the filtered supernatant was
centrifuged (125,000 × g for 2 h) over cushions
of 20% sucrose. The pellets were lysed and examined by immunoblot
analysis with anti-IN ( -IN) (top), anti-Vpr (middle), and
anti-Gag (bottom) antibodies as described earlier (57).
Vpr-IN-containing H16A virions were identical to the H12A virions (data
not shown). (B) The trans-IN protein rescues viral DNA
synthesis. Five hundred nanograms of wild-type virus and each of the
mutant viruses was used to infect cultures of HeLa-CD4 cells. After
4 h, the cell monolayers were washed, trypsinized, resuspended in
fetal bovine serum, and divided into two aliquots. One aliquot set was
analyzed by p24 antigen ELISA as described for Fig. 1. The other
aliquot set was placed back in culture medium at 37°C. At 18 h
postinfection, the cells were washed and total DNA was extracted by
organic methods. The extracts were normalized for intracellular
CA protein concentration and analyzed by PCR for viral DNA products of
reverse transcription as described for Fig. 1. The data are from a
representative experiment that was repeated three times, each time with
independent virus preparations.
|
|
trans-IN protein acts after virus assembly to promote viral DNA
synthesis.
To further analyze the effect of the IN protein on
reverse transcription, the RT-IN-minus provirus (S-RT) (57)
was complemented with the Vpr-RT fusion protein (Fig.
3A). While high RT activity levels were
associated with the progeny virions, they remained severely defective
in DNA synthesis. However, when S-RT virus was complemented with both
Vpr-RT and Vpr-IN together or with Vpr-RT-IN, viral DNA synthesis was
increased 40- to 80-fold compared with that of
Vpr-RT-complemented virions (Fig. 3B). By performing complementation experiments with the same virus background
(S-RT), we were able to directly examine the effect of the IN protein on reverse transcription. Taken together, these results strongly suggest that the failure of the IN mutant viruses to efficiently support reverse transcription was not due to a defect at the level of
Pr160Gag-Pol but, rather, that the mature IN protein is
important for viral DNA synthesis in vivo.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 3.
The trans-IN protein functions after virus
assembly and proteolytic processing. Four micrograms of
pSG3S-RT DNA was transfected into 293T cells ( ) or
cotransfected (+) with the Vpr-RT, Vpr- PCIN, and
Vpr-RT-IN expression vectors, respectively. (A) Immunoblot analysis.
Transfection-derived virions were concentrated from the culture
supernatants by ultracentrifugation (125,000 × g for
2 h) through cushions of 20% sucrose. The pellets were lysed and
examined by immunoblot analysis with anti-RT ( -RT), anti-IN,
anti-Vpr, and anti-Gag antibodies as indicated. (B) The
trans-IN protein is required for viral DNA synthesis. Five
hundred nanograms of the transfection-derived viruses was used to
infect cultures of HeLa-CD4 cells. DNA products of reverse
transcription were prepared and analyzed exactly as described above.
The data are from a representative experiment that was repeated three
times.
|
|
Additional evidence arguing against the notion that the
trans IN protein complements a defect during assembly comes
from our analysis of the cleavage-deficient Vpr-
PCIN
fusion protein. In parallel with the experiment described
above, S-RT virions were complemented with both Vpr-RT and
Vpr-
PCIN. Figure 3A (lane 3) shows that these virions
contained processed RT and minimal amounts of processed
Vpr-
PCIN (liberated IN protein was reduced by
approximately 10-fold [compare lanes 3 and 4]). For
Vpr-
PCIN-containing virions, no significant increase in
the synthesis of viral DNA compared with that of S-RT virions that were
complemented with only Vpr-RT was detected (Fig. 3B, compare lanes 3 and 4). Since the Vpr-IN and Vpr-
PCIN fusion proteins
are isogeneic (except for the amino acid substitution at position P1'
of the cleavage site) and both assemble into virions as an uncleaved
47-kDa fusion protein, this result indicates that free IN protein is
necessary for efficient reverse transcription.
Complementation between IN mutants.
By incorporating IN mutant
proteins that exhibited different phenotypes into virions, their
interdependence in supporting integration and reverse transcription
activities was analyzed. Figure 4A shows
that the integration-defective trans-IND116A
protein restored DNA synthesis to each of the DNA synthesis-defective (H12A, H16A, F185A, and
22) mutant viruses. To examine whether the
S-IN, H12A, H16A, F185A, and
22 IN mutants could support integration
of the provirus, each mutant was incorporated as a Vpr-IN mutant fusion
protein into the D116A mutant virus, which is DNA synthesis positive
and integration defective. Figure 4B shows that some but not all of the
Vpr-IN mutants were able to rescue viral DNA integration. The
trans-INF185A and
trans-IN
22 mutants markedly increased the
integration frequency. This result demonstrated that the F185A and
22 mutants still possessed the integration activity necessary to
catalyze provirus formation in vivo and that the integration and
reverse transcription functions of IN can occur independently. In
contrast, the trans-INH12A and
trans-INH16A mutants did not efficiently support
integration, indicating that mutations in the highly conserved HHCC
motif disturb both the reverse transcription and integration functions.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 4.
Complementation between different IN mutants. (A)
Enzymatically defective trans-IN protein supports reverse
transcription. Four micrograms of the S-IN, H12A, H16A, F185A, and
22 IN mutant proviral clones was transfected alone and separately
cotransfected into 293T cells with 2 µg of the
Vpr-IND116A or Vpr-IN expression vector. Forty-eight hours
later, supernatant virions were prepared and used to infect HeLa-CD4
cells exactly as described in the legend to Fig. 1. The infected cells
were washed 18 h later, and total DNA was extracted and treated
with DpnI endonuclease. The late R-gag DNA product of
reverse transcription was PCR amplified and analyzed as described
above. The data are from a representative experiment that was repeated
two times. (B) Complementation of proviral DNA integration. The D116A
IN mutant was inserted into the SG3 hygromycin-resistant clone,
generating Hy-SG3D116A. The Hy-SG3D116A mutant
virus produces wild-type levels of viral DNA yet is integration
defective. Four micrograms of Hy-SG3D116A was transfected
with 2 µg of the control vector (pLR2P) and individually
cotransfected with 2 µg of the Vpr-IN, Vpr-INH12A,
Vpr-INH16A, Vpr-INF185A, and
Vpr-IN 22 IN mutant expression vectors, respectively.
Since the env region of Hy-SG3D116A contains the
hygromycin resistance marker, the virions were pseudotyped by
including the pCMV-VSV-G env vector in the transfection
reactions. Forty-eight hours after transfection, the culture
supernatants were filtered through 0.45-µm-pore-size filters and
analyzed for HIV-1 p24 antigen concentration by ELISA. Twenty-five
nanograms (p24 antigen) of each pseudotyped virus stock was
used to infect cultures of HeLa cells. The infected cells were
maintained in hygromycin selection medium for 12 days and then
stained to identify resistant colonies. These results were highly
reproducible in three independent experiments. The data shown are
from a single representative experiment.
|
|
Virus type-specific IN is required for efficient viral DNA
synthesis.
To examine the specificity of these IN functions, the
HIV-2 IN protein (IN2) was incorporated into IN-minus
(S-IN) virions by expression as a Vpr-IN2 fusion protein.
Despite efficient virion incorporation and proteolytic processing
of Vpr-IN2 (data not shown), only a modest (2- to
3-fold) increase in HIV-1 DNA synthesis was observed, compared with a
10- to 20-fold increase induced by the homologous IN (Fig.
5A). However, when integration-defective mutant virus was complemented with Vpr-IN2, the integration
frequency was increased nearly 100-fold (Fig. 5B). This result
indicated that the HIV-2 IN protein was able to associate with the
HIV-1 reverse transcription complex but that this alone was not
sufficient to support DNA synthesis. This strongly suggests that
specific interactions between the homologous IN and other viral
components of the reverse transcription complex are required to promote
viral cDNA synthesis in vivo.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 5.
Analysis of heterologous IN. (A) HIV-2 IN protein
(IN2) does not efficiently support HIV-1 reverse
transcription. Four micrograms of pSG3S-IN was
cotransfected into 293T cells with 2 µg of the Vpr-IN,
Vpr-IN2, and pLR2P (vector only) expression vectors,
respectively. Four micrograms of pSG3wt was also
transfected as a control. Forty-eight hours later, supernatant virions
were prepared and used to infect HeLa-CD4 cells exactly as described in
the legend to Fig. 1. The infected cells were washed 18 h later,
and total DNA was extracted and treated with DpnI
endonuclease. Early (R-U5) and late (R-gag) viral DNA products of
reverse transcription were amplified by PCR and analyzed as described
above. The data are from a representative experiment that was repeated
three times, each time with independent virus preparations. (B)
Complementation of proviral DNA integration. To directly compare the
ability of the heterologous trans-IN2 protein to
support integration of the provirus with that of the homologous IN
protein, the hygromycin-resistant, integration-defective Hy-SG3
INAA35A clone was used for analysis. Hy-SG3
INAA35A contains a mutation in each of the three residues
that comprise the catalytic center of the IN protein (D64A, D116A, and
E152A) and efficiently synthesizes viral DNA after entry. Four
micrograms of Hy-SG3AA35A was cotransfected with 2 µg of
the Vpr-IN, and Vpr-IN2 expression plasmids, respectively.
The virions were pseudotyped by including the pCMV-VSV-G env
vector in the transfection reactions. Forty-eight hours after
transfection, the culture supernatants were filtered through
0.45-µm-pore-size filters and analyzed for HIV-1 p24 antigen
concentration by ELISA. Twenty-five nanograms (p24 antigen) of each of
the pseudotyped virus stocks was used to infect cultures of HeLa cells.
The infected cells were maintained in hygromycin selection medium for
12 days and then stained to identify resistant colonies as described
earlier (35). These results were highly reproducible in
three independent experiments. The data shown are from a single
representative experiment.
|
|
Direct physical interaction between the HIV-1 RT and IN
proteins.
One explanation for the effect of IN on reverse
transcription is that IN affects RT via a direct physical interaction.
Several observations suggest that HIV RT and IN may form a
heterodimeric complex: (i) the two proteins are known to coexist as a
complex in some retroviruses (30, 50), (ii) the
carboxy-terminal domain of RT (RNase H) and the central core domain of
IN are structurally similar (11, 14), and (iii) in
murine leukemia virus, IN and RT proteins can be coimmunoprecipitated
with antibodies to either protein (27). Therefore, we
examined whether a GST-HIV IN fusion protein would interact with an
HIV-1 RT heterodimer by using an in vitro binding assay. Figure
6B shows that the GST-IN protein efficiently pulls down recombinant RT heterodimer protein from crude
bacterial lysates. The specificity of RT-IN interaction was indicated
by the inability of empty G-beads or GST protein-bound G-beads to pull
down RT. The possibility that nucleic acids facilitated the association
of RT and IN proteins was ruled out by first pretreating the RT-IN
reaction mixture with micrococcal nuclease, which did not decrease the
amount of RT pulled down (Fig. 6C). The demonstration of a physical
interaction between RT and IN suggests that the two proteins exist as a
complex within the nucleoprotein reverse transcription complex. While
HIV-1 nuclear preintegration complexes have been shown to contain RT
(8, 42), no specific role for IN in reverse transcription
has been previously demonstrated.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 6.
Interaction between recombinant HIV-1 RT and IN
proteins. (A) Coomassie blue-stained gel showing the G-bead-bound GST
and GST-IN proteins used to pull-down the RT heterodimer. Equal
quantities of G-beads bound to no protein (lane 1), GST (lane 2), or
GST-IN (lane 3) were incubated with crude bacterial lysates in HND
buffer containing RT heterodimer. Following extensive washing, the
bound proteins were analyzed by SDS-PAGE. (B) Immunoblot analysis
showing RT-IN interaction. A duplicate gel run in parallel to that
shown in panel A was transferred to nitrocellulose and probed with the
5B2B2 anti-RT monoclonal antibody. The positions of p66 and p51
polypeptides are indicated. (C) The RT-IN interaction is resistant to
micrococcal nuclease digestion. The experiment was similar to that
described above except that the HND buffer contained 50 mM Tris-HCl (pH
8.0) and 1 mM CaCl2, and prior to addition of the bacterial
lysates, the samples were preincubated with 100 U of micrococcal
nuclease at 37°C for 10 min, and the nuclease was inactivated with
EGTA.
|
|
 |
DISCUSSION |
From assembly to integration of the provirus, the infectious HIV
structure progresses through a succession of precisely coordinated events involving many intra- and intermolecular interactions and rearrangements. A detailed understanding at the virus replication level
of the molecular mechanisms that are involved in assembly, maturation,
uncoating, and the early stages of reverse transcription remains
obscure. In part, this is due to the nature of the process by which the
virion proteins are assembled. In the later stages of the virus life
cycle, the structural proteins of the virion are synthesized and
assembled as precursor polyproteins. Each precursor plays a specific
role in the assembly process. After assembly, the structures of the Gag
and Gag-Pol precursor polyproteins change due to proteolytic
processing. Processing of the Gag and Gag-Pol precursors drives the
metamorphosis of the immature (noninfectious) virion into one with a
condensed, mature core structure containing the diploid single-stranded
viral RNA genome, nucleocapsid, RT, integrase, and primer tRNA (for a
review, see reference 48). In the early stage of the
virus life cycle, after entry into the host cell, the virus core
structure undergoes additional rearrangements (uncoating) to form a
nucleoprotein complex structure that supports reverse transcription.
After reverse transcription is completed, IN catalyzes integration of
the nascent viral cDNA into the host cell chromosomes. It is obvious
that mutations in IN (and other domains within Gag and Pol) can affect
both late- and early-stage events. As a result, it is inherently
difficult to specifically define the effect of such mutations on the
virus life cycle. In this study we used
trans-complementation methods to distinguish between the
effects of mutations in the mature IN protein and its function during
the early events of the virus life cycle versus the effects of
mutations in the Gag-Pol precursor protein and late stage events. For
the first time, our results show that the mature IN protein itself is
required for efficient reverse transcription, independent of its
enzymatic function. Moreover, our data indicate that the IN protein
promotes the initiation step of reverse transcription through virus
type-specific interactions with other components that comprise the
reverse transcription initiation complex.
Our analysis indicated that a change in the structure and function of
the Gag-Pol precursor protein was not responsible for the impairment of
viral DNA synthesis. Strong evidence for this comes from experiments
showing that trans-IN protein restores infectivity (Table 1)
and viral DNA synthesis (Fig. 2 and 3) to viruses that contain a
mutated Gag-Pol precursor protein. By analyzing IN mutant virions that
were complemented in trans with the cleavage-deficient
Vpr-
PCIN fusion protein, we further ruled out an
assembly defect that could have been complemented by the Vpr-IN fusion
protein. The Vpr-IN and Vpr-
PCIN fusion proteins are
identical, except for the single amino acid change at the P'
position (in the RT-IN cleavage site of Vpr-IN). Therefore, their
expression, transport to the surface of the infected cell, and assembly
into virions would likely be the same. However, the
Vpr-
PCIN fusion protein is unable to restore infectivity
and viral DNA synthesis above the levels of those for IN-minus virus,
indicating that the IN protein supports viral DNA synthesis after virus
assembly and proteolytic processing. It is noteworthy that some
mature IN protein is detected in virions complemented with the
Vpr-
PCIN fusion protein (Fig. 3A), yet the virions
remain noninfectious. It is likely that the mutation at the P' residue
reduces not only the total extent of cleavage but also the rate at
which IN is liberated, which in turn could alter the proper association
of IN with the reverse transcription complex during condensation of the virus core. Additional evidence that changes in the
structure of the Gag-Pol precursor protein were not responsible for the defect in viral DNA synthesis comes in part from our earlier results, which demonstrated that the Vpr-RT-IN fusion protein, but not the
Vpr-RT fusion protein, could efficiently complement (>80% of
wild-type levels) the defect in infectivity of RT-IN-minus virus (S-RT)
(57). We have now extended those findings by analyzing whether the S-RT mutant virions synthesized viral DNA when complemented with only the Vpr-RT fusion protein. Our data clearly show
that in the absence of IN, RT is not sufficient to overcome the defect, even though proteolytic processing of the Gag precursor protein, maturation of the virus particle, and RT/p24 ratios were similar to
those for RT-IN-minus virions that were complemented with either Vpr-RT
and Vpr-IN together or with Vpr-RT-IN. These results are consistent
with the failure of IN-minus virus (S-IN) to synthesize viral DNA.
Taken together, these results indicate that the defect in reverse
transcription was principally due to changes in the mature IN protein.
Our data suggest that IN is an integral component of the nucleoprotein
reverse transcription complex and that through interactions with
other components (such as RT, genomic RNA, or tRNA), it is necessary for efficient initiation of viral DNA synthesis. Mutations in
the IN protein could change the structure of the reverse transcription complex, which could in turn have a negative effect on reverse transcription. On the other hand, it is also possible that the IN protein directly promotes reverse transcription through specific interactions with other crucial components of the reverse transcription complex. The fact that the wild-type trans-IN protein
(Vpr-IN) restores DNA synthesis to IN mutant viruses (H12A, H16A,
F185A, and
22) indicates that mutant IN protein does not
irreversibly disrupt the nucleoprotein complex. However, this result
does not exclude the possibility either that the IN mutants fail to
associate with the nucleoprotein complex or that they are displaced by
the wild-type trans-IN protein. On the contrary, our
results indicate that IN mutant proteins do associate with the
nucleoprotein preintegration complex. Figure 4 shows that the
trans-F185A IN mutant (which did not support reverse
transcription) restores integration to D116A mutant virions. Moreover,
complementation of the IN mutant viruses (F185A and
22) with the
trans-D116A IN mutant (Vpr-IND116A) restored DNA
synthesis and integration (Fig. 4). Similarly, the heterologous HIV-2
trans-IN protein also efficiently supported integration of
HIV-1 DNA but did not support reverse transcription, indicating that
the HIV-2 IN protein does associate with the nucleoprotein preintegration complex (Fig. 5). The results of our
trans-complementation experiments and our data showing a
direct physical interaction between IN and RT clearly show that the
mere association of the IN protein with the nucleoprotein complex is
not sufficient for DNA synthesis but rather that
the IN protein promotes reverse transcription through
virus-specific (not cellular) interactions with other viral
components in the reverse transcription complex.
Recent studies have suggested that reverse transcription may be
regulated at three defined stages: initiation, transition (the point
between initiation and elongation), and elongation (34). The
efficiency of initiation requires specific and multiple interactions
between viral and cellular components, including the viral RNA genome,
RT, nucleocapsid, and primer tRNA. Also included are interactions of
the primer tRNA with the primer binding site and an A-rich loop
located 12 to 17 nucleotides upstream of the primer binding site
(28, 55). Disturbances of any of these interactions may
cause defects in the initiation of reverse transcription in vivo.
Initiation is a slow process and proceeds at a highly reduced
processivity compared with elongation (34). This functional
distinction suggests that the structures and compositions of the
initiation and elongation complexes are different. Our analysis of
viral DNA elongation shows that for the H12A, H16A, F185A, and
22 IN
mutant viruses, the minus-strand strong-stop DNA product was produced
in amounts similar to those of the intermediate and late DNA products.
Also, it was shown that the trans-IN protein supported the
synthesis of minus-strand strong-stop DNA to an extent similar to that
for later DNA products. These results indicate that the IN protein is
required either prior to or at the initiation stage of reverse
transcription. Our data clearly exclude a defect at the level of virus
entry (Table 1). Moreover, it seems unlikely that IN protein supports
uncoating after virus entry. Recent studies with nef and
certain gag mutant viruses have shown that defects in
uncoating, which impair virus DNA synthesis, can be overcome if the
normal virus entry pathway is bypassed via pseudotyping with the
VSV-G envelope (1). Our data show that VSV-G
pseudotyping of IN mutant viruses did not overcome the defect in
infectivity. Our findings that show a direct physical interaction
between the IN and RT proteins strongly suggest that the IN protein is
directly involved in reverse transcription in vivo. In the case of the avian retroviruses, the IN protein comprises an integral
component of the RT heterodimer; an RT-IN polypeptide makes up the beta subunit (30, 50). Taken together, these results suggest that the IN protein forms an integral part of the reverse transcription initiation complex and specifically promotes interactions between RT,
the genomic RNA, and primer tRNA3Lys that facilitate initiation.
The apparent fragility of the reverse transcription initiation complex
(34) and the sensitivity of reverse transcription to
mutations in any of the three IN subdomains may suggest that the DNA
synthesis function of IN could be particularly vulnerable to anti-IN
compounds. Of particular interest is the fact that disturbances in the
highly conserved HHCC motif caused defects in virus replication at two
levels, in both reverse transcription and integration (Fig. 4).
Therefore, it is possible that drugs which target this motif could
inhibit virus replication at both levels. Finally, our findings
validate a novel and powerful approach to dissect important molecular
processes of HIV-1 at the virus replication level.
 |
ACKNOWLEDGMENTS |
We thank Alan Engelman (Division of Human Retroviruses,
Dana-Farber Cancer Institute) for providing the HIV-1 proviral clone mutated at position 185 (F185A) of IN and Stephen Hughes (ABL-Basic Research Program, NCI, Frederick Cancer Research and Development Center) for review of the manuscript and helpful discussions.
This research was supported by National Institutes of Health grants
CA73470 and AI39951 (to G.V.K.), and facilities of the Central AIDS
Virus and Protein Expression Cores of the Birmingham Center for AIDS
Research (grant P30-AI-27767). This research was also supported by a
Merit Review Award funded by the Office of Research and Development,
Medical Research Services, Department of Veterans Affairs.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: University of
Alabama at Birmingham, Department of Medicine, 1900 University
Blvd., THT 513H, Birmingham, AL 35294. Phone: (205) 934-0051. Fax: (205) 975-7300. E-mail: KappesJC{at}uab.edu.
 |
REFERENCES |
| 1.
|
Aiken, C.
1997.
Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.
J. Virol.
71:5871-5877[Abstract].
|
| 2.
|
Aiken, C., and D. Trono.
1995.
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis.
J. Virol.
69:5048-5056[Abstract].
|
| 3.
|
Ansari-Lari, M. A., and R. A. Gibbs.
1996.
Expression of human immunodeficiency virus type 1 reverse transcriptase in trans during virion release and after infection.
J. Virol.
70:3870-3875[Abstract].
|
| 4.
|
Braaten, D.,
E. K. Franke, and J. Luban.
1996.
Cyclophilin A is required for an early step in the virus life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription.
J. Virol.
70:3551-3560[Abstract].
|
| 5.
|
Brown, P.
1997.
Integration, p. 161-204.
In
J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 6.
|
Brown, P. O.,
B. Bowerman,
H. E. Varmus, and J. M. Bishop.
1989.
Retroviral integration: structure of the initial covalent complex and its precursor, and a role for the viral IN protein.
Proc. Natl. Acad. Sci. USA
86:2525-2529[Abstract/Free Full Text].
|
| 7.
|
Bukovsky, A., and H. Göttlinger.
1996.
Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease.
J. Virol.
70:6820-6825[Abstract/Free Full Text].
|
| 8.
|
Bukrinsky, M. I.,
N. Sharova,
T. L. McDonald,
T. Pushkarskaya,
W. G. Tarpley, and M. Stevenson.
1993.
Association of integrase, matrix and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection.
Proc. Natl. Acad. Sci. USA
90:6125-6129[Abstract/Free Full Text].
|
| 9.
|
Camuar, D., and D. Trono.
1996.
Characterization of human immunodeficiency virus type 1 Vif particle incorporation.
J. Virol.
70:6106-6111[Abstract].
|
| 10.
|
Cannon, P. M.,
E. D. Byles,
S. M. Kingsman, and A. J. Kingsman.
1996.
Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication.
J. Virol.
70:651-657[Abstract].
|
| 11.
|
Davies, J. F.,
Z. Hostomska,
Z. Hostomsky,
S. R. Jordan, and D. A. Matthews.
1991.
Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase.
Science
252:88-95[Abstract/Free Full Text].
|
| 12.
|
Drelich, M.,
R. Wilhelm, and J. Mous.
1992.
Identification of amino acid residues critical for endonuclease and integration activities of HIV-1 IN in vitro.
Virology
188:459-468[Medline].
|
| 13.
|
Dubay, J. W.,
S. J. Roberts,
B. H. Hahn, and E. Hunter.
1992.
Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity.
J. Virol.
66:6616-6625[Abstract/Free Full Text].
|
| 14.
|
Dyda, F.,
A. B. Hickman,
T. M. Jenkins,
A. Engelman,
R. Craigie, and D. R. Davies.
1994.
Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases.
Science
266:1981-1986[Abstract/Free Full Text].
|
| 15.
|
Engelman, A., and R. Craigie.
1992.
Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro.
J. Virol.
66:6361-6369[Abstract/Free Full Text].
|
| 16.
|
Engelman, A.,
G. Englund,
J. M. Orenstein,
M. A. Martin, and R. Craigie.
1995.
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication.
J. Virol.
69:2729-2736[Abstract].
|
| 17.
|
Engelman, A.,
Y. Liu,
H. Chen,
M. Farzan, and F. Dyda.
1997.
Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase.
J. Virol.
71:3507-3514[Abstract].
|
| 18.
|
Farnet, C. M., and F. D. Bushman.
1997.
HIV-1 cDNA integration: requirement of HMGI(Y) protein for function of preintegration complexes in vitro.
Cell
88:483-492[Medline].
|
| 19.
|
Farnet, C. M., and W. A. Haseltine.
1991.
Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex.
J. Virol.
65:1910-1915[Abstract/Free Full Text].
|
| 20.
|
Fletcher, T. M., III,
M. A. Soares,
S. McPhearson,
H. Hui,
M. Wiskerchen,
M. A. Muesing,
G. M. Shaw,
A. D. Leavitt,
J. D. Boeke, and B. H. Hahn.
1997.
Complementation of integrase function in HIV-1 virions.
EMBO J.
16:5123-5138[Medline].
|
| 21.
|
Franke, E. K.,
H. E. Yuan, and J. Luban.
1994.
Specific incorporation of cyclophilin A into HIV-1 virions.
Nature
372:359-362[Medline].
|
| 22.
|
Fujiwara, T., and K. Mizuuchi.
1988.
Retroviral DNA integration: structure of an integration intermediate.
Cell
54:497-504[Medline].
|
| 23.
|
Gallay, P.,
S. Swingler,
J. Song,
F. Bushman, and D. Trono.
1995.
HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase.
Cell
83:569-576[Medline].
|
| 24.
|
Guo, J.,
L. E. Henderson,
J. Bess,
B. Kane, and J. G. Levin.
1997.
Human immunodeficiency virus type 1 nucleocapsid protein promotes efficient strand transfer and specific viral DNA synthesis by inhibiting TAR-dependent self-priming from minus-strand strong-stop DNA.
J. Virol.
71:5178-5188[Abstract].
|
| 25.
|
Harrich, D.,
C. Ulich,
L. F. Gracia-Martinez, and R. B. Gaynor.
1997.
Tat is required for efficient HIV-1 reverse transcription.
EMBO J.
16:1224-1235[Medline].
|
| 26.
|
Heinzinger, N. K.,
M. I. Bukrinsky,
S. A. Haggerty,
A. M. Ragland,
V. Kewalramani,
M.-A. Lee,
H. E. Gendelman,
L. Ratner,
M. Stevenson, and M. Emerman.
1994.
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.
Proc. Natl. Acad. Sci. USA
91:7311-7315[Abstract/Free Full Text].
|
| 27.
|
Hu, S. C.,
D. L. Court,
M. Zweig, and J. G. Levin.
1986.
Murine leukemia virus pol gene products: analysis with antisera generated against reverse transcriptase and endonuclease fusion proteins expressed in Escherichia coli.
J. Virol.
60:267-274[Abstract/Free Full Text].
|
| 28.
|
Isel, C.,
C. Ehresmann,
G. Keith,
B. Ehresmann, and R. Marquet.
1995.
Initiation of reverse transcription of HIV-1: secondary structure of the HIV-1 RNA/tRNALys,3.
J. Mol. Biol.
247:236-250[Medline].
|
| 29.
|
Kalpana, G. V.,
S. Marmon,
W. Wang,
G. R. Crabtree, and S. P. Goff.
1994.
Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5.
Science
266:2002-2006[Abstract/Free Full Text].
|
| 30.
|
Katz, R. A., and A. M. Skalka.
1994.
The retroviral enzymes.
Annu. Rev. Biochem.
63:133-173[Medline].
|
| 31.
|
Kew, Y.,
S. Qingbin, and V. R. Prasad.
1994.
Subunit-selective mutagenesis of Glu-89 residue in human immunodeficiency virus reverse transcriptase.
J. Biol. Chem.
269:15331-15336[Abstract/Free Full Text].
|
| 32.
|
Kimpton, J., and M. Emerman.
1992.
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated -galactosidase gene.
J. Virol.
66:2232-2239[Abstract/Free Full Text].
|
| 33.
|
Kulkosky, J.,
K. S. Jones,
R. A. Katz,
J. P. G. Mack, and A. M. Skalka.
1992.
Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases.
Mol. Cell. Biol.
12:2331-2338[Abstract/Free Full Text].
|
| 34.
|
Lanchy, J.-M.,
C. Ehresmann,
S. F. J. Le Grice,
B. Ehresmann, and R. Marquet.
1996.
Binding and kinetic properties of HIV-1 reverse transcription markedly differ during initiation and elongation of reverse transcription.
EMBO J.
15:7178-7187[Medline].
|
| 35.
|
Leavitt, A. D.,
G. Robles,
N. Alesandro, and H. E. Varmus.
1996.
Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection.
J. Virol.
70:721-728[Abstract].
|
| 36.
|
Leavitt, A. D.,
L. Shiue, and H. E. Varmus.
1993.
Site-directed mutagenesis of HIV-1 integrase demonstrates differential effects on integrase functions in vitro.
J. Biol. Chem.
268:2113-2119[Abstract/Free Full Text].
|
| 37.
|
Li, X.,
Y. Quan,
E. J. Arts,
Z. Li,
B. D. Preston,
H. DeRocquigny,
B. P. Roques,
J.-L. Darliz,
L. Kleiman,
M. A. Parniak, and M. A. Wainberg.
1996.
Human immunodeficiency virus type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNA3Lys in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site.
J. Virol.
70:4996-5004[Abstract/Free Full Text].
|
| 38.
|
Liu, H.,
X. Wu,
M. Newman,
G. M. Shaw,
B. H. Hahn, and J. C. Kappes.
1995.
The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures.
J. Virol.
69:7630-7638[Abstract].
|
| 39.
|
Liu, H.,
X. Wu,
H. Xiao,
J. A. Conway, and J. C. Kappes.
1997.
Incorporation of functional human immunodeficiency virus type 1 integrase into virions independent of the Gag/Pol precursor protein.
J. Virol.
71:7701-7710.
|
| 40.
|
Luban, J.,
K. Bossolt,
E. Franke,
G. V. Kaplan, and S. P. Goff.
1993.
Human immunodeficiency virus type 1 gag protein binds to cyclophilins A and B.
Cell
73:1067-1068[Medline].
|
| 41.
|
Masuda, T.,
V. Planelles,
P. Krogstad, and I. S. Y. Chen.
1995.
Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain.
J. Virol.
69:6687-6696[Abstract].
|
| 42.
|
Miller, M. D.,
C. M. Farnet, and F. D. Bushman.
1997.
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition.
J. Virol.
71:5382-5390[Abstract].
|
| 43.
|
Pauza, C. D.
1990.
Two bases are deleted from the termini of HIV-1 linear DNA during integrative recombination.
Virology
179:886-889[Medline].
|
| 44.
|
Quillent, C.,
A. M. Borman,
S. Paulous,
C. Dauguet, and F. Clavel.
1996.
Extensive regions of pol are required for efficient human immunodeficiency virus polyprotein processing and particle maturation.
Virology
219:29-36[Medline].
|
| 45.
|
Schwartz, O.,
V. Marechal,
O. Danos, and J.-M. Heard.
1995.
Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell.
J. Virol.
69:4053-4059[Abstract].
|
| 46.
|
Shin, C.-G.,
B. Taddeo,
W. A. Haseltine, and C. M. Farnet.
1994.
Genetic analysis of the human immunodeficiency virus type 1 integrase protein.
J. Virol.
68:1633-1642[Abstract/Free Full Text].
|
| 47.
|
Sova, P., and D. J. Volsky.
1993.
Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with Vif-negative human immunodeficiency virus type 1.
J. Virol.
67:6322-6326[Abstract/Free Full Text].
|
| 48.
|
Swanstrom, R., and J. W. Wills.
1997.
Synthesis, assembly, and processing of viral proteins, p. 263-334.
In
J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 49.
|
Thali, M.,
M. A. Bukovsky,
E. Kondo,
B. Rosenwirth,
C. T. Walsh,
J. Sodroski, and H. G. Göttlinger.
1994.
Functional association of cyclophilin A with HIV-1 virions.
Nature
372:363-365[Medline].
|
| 50.
|
Trentin, B.,
N. Rebeyrotte, and R. Z. Mamoun.
1998.
Human T-cell leukemia virus type 1 reverse transcriptase (RT) originates from the pro and pol open reading frames and requires the presence of RT-RNase H (RH) and RT-RH-integrase proteins for its activity.
J. Virol.
72:6504-6510[Abstract/Free Full Text].
|
| 51.
|
van Gent, D. C.,
A. A. M. Oude Groeneger, and R. H. A. Plasterk.
1992.
Mutational analysis of the integrase protein of human immunodeficiency virus type 2.
Proc. Natl. Acad. Sci. USA
89:9598-9601[Abstract/Free Full Text].
|
| 52.
|
Vincent, K. A.,
V. Ellison,
S. A. Chow, and P. O. Brown.
1993.
Characterization of human immunodeficiency virus type 1 integrase expressed in Escherichia coli and analysis of variants with amino-terminal mutations.
J. Virol.
67:425-437[Abstract/Free Full Text].
|
| 53.
|
Vink, C., and R. H. A. Plasterk.
1993.
The immunodeficiency virus integrase protein.
Trends Genet.
9:433-437[Medline].
|
| 54.
|
von Schwedler, U.,
J. Song,
C. Aiken, and D. Trono.
1993.
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.
J. Virol.
67:4945-4955[Abstract/Free Full Text].
|
| 55.
|
Wakefield, J. K.,
S.-M. Kang, and C. D. Morrow.
1996.
Construction of a type 1 human immunodeficiency virus that maintains a primer binding site complementary to tRNAHis.
J. Virol.
70:966-975[Abstract].
|
| 56.
|
Wiskerchen, M., and M. A. Muesing.
1995.
Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells.
J. Virol.
69:376-386[Abstract].
|
| 57.
|
Wu, X.,
H. Liu,
H. Xiao,
J. A. Conway,
E. Hunter, and J. C. Kappes.
1997.
Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein.
EMBO J.
16:5113-5122[Medline].
|
| 58.
|
Wu, X.,
H. Liu,
H. Xiao,
J. A. Conway, and J. C. Kappes.
1996.
Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles.
J. Virol.
70:3378-3384[Abstract].
|
| 59.
|
Wu, X.,
H. O. Liu,
H. Xiao,
J. Kim,
P. Seshaiah,
G. Natsoulis,
J. D. Boeke,
B. H. Hahn, and J. C. Kappes.
1995.
Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx.
J. Virol.
69:3389-3398[Abstract].
|
Journal of Virology, March 1999, p. 2126-2135, Vol. 73, No. 3
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Malet, I., Delelis, O., Valantin, M.-A., Montes, B., Soulie, C., Wirden, M., Tchertanov, L., Peytavin, G., Reynes, J., Mouscadet, J.-F., Katlama, C., Calvez, V., Marcelin, A.-G.
(2008). Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro. Antimicrob. Agents Chemother.
52: 1351-1358
[Abstract]
[Full Text]
-
Dobard, C. W., Briones, M. S., Chow, S. A.
(2007). Molecular Mechanisms by Which Human Immunodeficiency Virus Type 1 Integrase Stimulates the Early Steps of Reverse Transcription. J. Virol.
81: 10037-10046
[Abstract]
[Full Text]
-
Mousnier, A., Kubat, N., Massias-Simon, A., Segeral, E., Rain, J.-C., Benarous, R., Emiliani, S., Dargemont, C.
(2007). von Hippel Lindau binding protein 1-mediated degradation of integrase affects HIV-1 gene expression at a postintegration step. Proc. Natl. Acad. Sci. USA
104: 13615-13620
[Abstract]
[Full Text]
-
Liao, W.-H., Huang, K.-J., Chang, Y.-F., Wang, S.-M., Tseng, Y.-T., Chiang, C.-C., Wang, J.-J., Wang, C.-T.
(2007). Incorporation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase into Virus-Like Particles. J. Virol.
81: 5155-5165
[Abstract]